Kathryn A Phillips PhD

@kathrynp-phd.bsky.social

Professor Health Econ/Health Services Research @UCSF. Founder @UCSF_TRANSPERS, focused on effective/efficient/equitable implementation of emerging technologies. Founding Editor-in-Chief #HAScholar @Health_Affairs – OA journal emerging/global health policy.

What shapes FDA drug approval beyond clinical evidence? @Health_Affairs Scholar Editor's Choice article found just 15 empirical studies & findings on potential influences were mixed leaving more to learn about regulatory decision-making. academic.oup.com/healthaffair...

Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review

AbstractIntroduction. The Food and Drug Administration's (FDA) approval decisions are expected to rest primarily on clinical evidence, yet concerns persist

academic.oup.com

How does Oregon’s regulated psilocybin model work for prospective clients w/ psychiatric histories? Editor's Choice article @Health_Affairs Scholar found clinically cautious practices. But with median cost of $1,900 and financial strain, scalability remains a challenge. doi.org/10.1093/hasc...

“Am I a candidate for magic mushrooms?” A mystery shopper study of Oregon psilocybin service centers

AbstractIntroduction. Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what pr

academic.oup.com

Could reducing nicotine in cigarettes help more people quit? An Editor's Choice article @Health_Affairs Scholar argue a federal nicotine cap be paired w/ stronger cessation support & clear, evidence-based communication on relative risks of tobacco & nicotine products academic.oup.com/healthaffair...

Implementing a Nicotine Cap to Make America Healthy Again

Abstract. The U.S. Department of Health and Human Services’ (HHS) 'Make America Healthy Again' initiative cannot eradicate the root causes of the nation’s

academic.oup.com

The GLP-1 era underscores something we know about nutrition and metabolic care: one size does not fit all. Precision nutrition is an emerging field that could help us better target dietary, metabolic & drug interventions. But realizing that potential will take more than scientific advances.

Thoughtful guidance- all should read. My only addition is that uploading manuscripts by reviewers into SECURE INTERNAL AI chatbots (we have at UCSF) should be OK - table just says "external prohibited". Updated Guidance for Author Use of AI in Medical Publication jamanetwork.com/journals/jam...

Updated Guidance for Author Use of AI in Medical Publication

Artificial intelligence (AI) is reshaping research and scientific publishing at an unprecedented pace, with extraordinary promise. We as editors embrace AI as a tool that can be helpful to researchers...

jamanetwork.com

Health Affairs Scholar turns 3! 📈Rapid growth: Submissions up 66% ️⏱️Speed/rigor: Among fastest peer review & publication 📍Innovation and inclusion: New article types & fast-track publication pathways ⭐ Growing impact: In top 25% most-cited health policy journals academic.oup.com/healthaffair...

Health affairs scholar at year 3: rapid growth, global reach, real-world impact

Three years ago, we launched Health Affairs Scholar: Emerging and Global Health Policy (“Scholar”) to meet a clear need: a health policy journal that is op

academic.oup.com

What should health policy researchers study next? @Health_Affairs Scholar Editorial Team published new article, building on widely disseminated 2023 editorial. Access, delivery, corporatization, pharmaceuticals, international health, AI, precision nutrition,climate. academic.oup.com/healthaffair...

Ten high-priority areas for health policy research in 2026-2027

Abstract. Health policy is undergoing a period of rapid transformation, driven by major health reforms, changing market structures, pharmaceutical policy d

academic.oup.com

If insurer won't pay for multicancer early detection test, should it pay for PET scans, CT scans, MRIs, & biopsies that follow a positive result? - We interviewed 16 major U.S. private payers. - None covered MCED testing. - Most said would cover some confirmatory diagnostics—but case by case.